These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6160553)

  • 1. Electrophysiologic properties of hydralazine in man.
    Gould L; Reddy CV; Zen B; Singh BK; Becker WH
    Pacing Clin Electrophysiol; 1980 Sep; 3(5):548-54. PubMed ID: 6160553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure.
    Mason DT
    Am J Med; 1978 Jul; 65(1):106-25. PubMed ID: 99030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure.
    Gogia H; Mehra A; Parikh S; Raman M; Ajit-Uppal J; Johnson JV; Elkayam U
    J Am Coll Cardiol; 1995 Dec; 26(7):1575-80. PubMed ID: 7594088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Afterload reduction in the treatment of cardiac failure.
    Mason DT
    Schweiz Med Wochenschr; 1978 Nov; 108(44):1695-703. PubMed ID: 102028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines for vasodilator therapy of congestive heart failure in infants and children.
    Artman M; Graham TP
    Am Heart J; 1987 Apr; 113(4):994-1005. PubMed ID: 3031972
    [No Abstract]   [Full Text] [Related]  

  • 6. [Peripheral vasodilator agents in cardiology].
    Khomenko VL; Pomerantsev VP; Vasiuk IuA
    Sov Med; 1980; (12):70-5. PubMed ID: 6784251
    [No Abstract]   [Full Text] [Related]  

  • 7. Hemodynamic advantage of combined administration of hydralazine orally and nitrates nonparenterally in the vasodilator therapy of chronic heart failure.
    Massie B; Chatterjee K; Werner J; Greenberg B; Hart R; Parmley WW
    Am J Cardiol; 1977 Nov; 40(5):794-801. PubMed ID: 411364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination vasodilator therapy for severe chronic congestive heart failure.
    Chatterjee K; Drew D; Parmley WW; Klausner SC; Polansky J; Zacherle B
    Ann Intern Med; 1976 Oct; 85(4):467-70. PubMed ID: 823852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outpatient vasodilator therapy of congestive heart failure. Consideration of agents at rest and during exercise.
    Chatterjee K; Massie B; Rubin S; Gelberg H; Brundage BH; Ports TA
    Am J Med; 1978 Jul; 65(1):134-45. PubMed ID: 99031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-parenteral combined afterload and preload reduction therapy in congestive heart failure.
    Mehta J; Pepine CJ; Conti CR
    Clin Cardiol; 1978 Aug; 1(2):68-73. PubMed ID: 116791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic responsiveness to short- and long-acting vasodilators in left ventricular failure.
    Franciosa JA; Cohn JN
    Am J Med; 1978 Jul; 65(1):126-33. PubMed ID: 685986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The treatment of congestive heart failure by using vasodilators. I. Physiological basis. Different vasodilators (author's transl)].
    Solignac A
    Nouv Presse Med; 1978 Mar; 7(12):1013-20. PubMed ID: 96422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative haemodynamic effects of intravenous nisoldipine and hydralazine in congestive heart failure.
    Haitas B; Meyer TE; Angel ME; Reef E
    Br J Clin Pharmacol; 1990 Mar; 29(3):366-8. PubMed ID: 2310661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New nitrate indications].
    Schrey A
    Adv Clin Pharmacol; 1978; 17():1-54. PubMed ID: 98966
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular clinical pharmacology of impedance reducing agents.
    Franciosa JA; Pierpont G
    J Chronic Dis; 1981; 34(7):341-52. PubMed ID: 6788789
    [No Abstract]   [Full Text] [Related]  

  • 16. Afterload reduction in the management of congestive heart failure following acute myocardial infarction.
    Miller RR; Awan NA; Mason DT
    Adv Cardiol; 1978; 23():173-81. PubMed ID: 345758
    [No Abstract]   [Full Text] [Related]  

  • 17. [Recent progress in the treatment of cardiac insufficiency. Contribution of vasodilator agents].
    Ivanciuc I
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1979; 31(5):385-92. PubMed ID: 44561
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of vasodilator therapy in the management of the patient with acute myocardial infarction.
    Wagner GC; Robinson PH
    Prim Care; 1981 Sep; 8(3):467-81. PubMed ID: 6796986
    [No Abstract]   [Full Text] [Related]  

  • 19. Electrophysiologic properties of nitroprusside in man.
    Gould L; Reddy R; Kim SG; Oh KC
    Angiology; 1979 Dec; 30(12):841-9. PubMed ID: 533014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Provocation of myocardial ischemic events during initiation of vasodilator therapy for severe chronic heart failure. Clinical and hemodynamic evaluation of 52 consecutive patients with ischemic cardiomyopathy.
    Packer M; Meller J; Medina N; Yushak M; Gorlin R
    Am J Cardiol; 1981 Nov; 48(5):939-46. PubMed ID: 7304442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.